Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
Ontology highlight
ABSTRACT: Acute myeloid leukemia (AML) bears heterogeneous cells that can consequently offset killing by single-CAR-based therapy, which results in disease relapse. Leukemic stem cells (LSCs) associated with CD123 expression comprise a rare population that also plays an important role in disease progression and relapse. Here, we report on the robust anti-tumor activity of a compound CAR (cCAR) T-cell possessing discrete scFv domains targeting two different AML antigens, CD123, and CD33, simultaneously. We determined that the resulting cCAR T-cells possessed consistent, potent, and directed cytotoxicity against each target antigen population. Using four leukemia mouse models, we found superior in vivo survival after cCAR treatment. We also designed an alemtuzumab safety-switch that allowed for rapid
SUBMITTER: Petrov JC
PROVIDER: S-EPMC5990523 | biostudies-literature | 2018 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA